News about " AI-driven drug discovery"

Evogene and Tel Aviv University Launch AI Drug Discovery Initiative

Evogene and Tel Aviv University Launch AI Drug Discovery Initiative

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have launched a joint initiative combining Artificial Intelligence (AI)-driven computational chemistry with advanced experimental capabilities to accelerate small-molecule drug discovery.

AI-driven Drug Discovery | 08/07/2026 | By News Bureau 100

Insilico Medicine And SK Biopharmaceuticals Achieve AI-Powered Drug Discovery Collaboration for Neuroimmune Disorders

Insilico Medicine And SK Biopharmaceuticals Achieve AI-Powered Drug Discovery Collaboration for Neuroimmune Disorders

Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.

AI-driven Drug Discovery | 23/06/2026 | By News Bureau 413

Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969

Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969

Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.

AI-driven Drug Discovery | 18/06/2026 | By News Bureau

Evotec SE and Almirall S.A. Advance Dermatology Drug Candidate to Preclinical Stage

Evotec SE and Almirall S.A. Advance Dermatology Drug Candidate to Preclinical Stage

The Evotec–Almirall collaboration showcases the power of AI-driven drug discovery, rapidly advancing a promising dermatology candidate toward clinical development for unmet medical needs.

AI-driven Drug Discovery | 05/05/2026 | By News Bureau

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.

AI Driven Drug Discovery | 09/03/2026 | By News Bureau 226

Illumina Launches Billion Cell Atlas to Power AI-Driven Drug Discovery

Illumina Launches Billion Cell Atlas to Power AI-Driven Drug Discovery

Illumina, Inc. has launched the Illumina Billion Cell Atlas, the world’s largest genome-wide genetic perturbation dataset, designed to accelerate AI-enabled drug discovery across the pharmaceutical industry.

AI-Driven Drug Discovery | 15/01/2026 | By Darshana 271

Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration

Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration

The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.

AI-driven Drug Discovery | 09/01/2026 | By News Bureau 263

Insilico Medicine and Servier Forge AI-Driven Oncology Drug Discovery Alliance

Insilico Medicine and Servier Forge AI-Driven Oncology Drug Discovery Alliance

Insilico Medicine, a global leader in artificial intelligence–driven drug discovery, has entered into a multi-year research and development collaboration with Servier, an independent international pharmaceutical company governed by a foundation.

AI-Driven Drug Discovery | 06/01/2026 | By Darshana 115

Merck KGaA Inks Up to USD 3 Billion AI-Driven Drug Discovery Deal with Valo Health

Merck KGaA Inks Up to USD 3 Billion AI-Driven Drug Discovery Deal with Valo Health

Merck KGaA has entered into a major strategic collaboration with Valo Health to use Valo’s AI-powered human causal biology platform for discovering and developing new treatments for Parkinson’s disease and related disorders.

AI-Driven Drug Discovery | 21/11/2025 | By Darshana 505

Bahrain's sovereign fund partners with SandboxAQ to accelerate AI-driven drug discovery

Bahrain's sovereign fund partners with SandboxAQ to accelerate AI-driven drug discovery

Bahrain’s sovereign wealth fund, Mumtalakat, has entered into a strategic partnership with SandboxAQ, a USA-based company specialising in artificial intelligence and quantum technologies, to fast-track drug discovery and build biotech assets valued at up to USD 1 billion.

AI-driven Drug Discovery | 28/10/2025 | By Darshana 327


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members